Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis...

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Cancer vaccines are effective against virus-related cancers but less so for virus-irrelevant ones.
• Preconditioning tumor cells with cytotoxic drugs can create vaccines, but their immunogenicity is often insufficient for treating existing tumors.

Purpose of the Study:

• To identify a drug that can generate potent whole-cell tumor vaccines for both prophylactic and therapeutic cancer treatment.
• To elucidate the mechanisms underlying the efficacy of these vaccines, including cell death pathways and immune signaling.

Main Methods:

• Multiparameter screening to identify arsenic trioxide (ATO) as a suitable drug.
• Generating whole-cell tumor vaccines by preconditioning tumor cells with ATO.
• Utilizing CRISPR-Cas9 to knock out key cell death executors (Rip3, Mlkl, Acsl4).
• Investigating the role of CD8+ T cells, interferon signaling, and danger molecules.
• Evaluating the synergistic effect of PD-1 blockade.

Main Results:

• ATO preconditioning yielded whole-cell tumor vaccines with significant antineoplastic effects in prophylactic and therapeutic models.
• Vaccine efficacy depended on CD8+ T cells, type I and II interferon signaling, and danger molecule release.
• ATO-induced cell death involved autophagy, apoptosis, necroptosis, and ferroptosis.
• Knocking out Rip3, Mlkl, or Acsl4 abolished vaccine efficacy, which could be restored by danger molecule analogs.
• PD-1 blockade enhanced therapeutic efficacy by increasing local IFN-γ production.

Conclusions:

• Arsenic trioxide is a potent drug for generating effective whole-cell cancer vaccines.
• The efficacy of ATO-based vaccines is critically dependent on specific cell death pathways and immune signaling.
• Combining ATO-based vaccines with PD-1 blockade offers a promising strategy for cancer immunotherapy.